|  | Cancer | Lymphoma

Lymphocyte Production: Bone Marrow, Thymus & Peripheral Maturation

Lymphocytes (B cells, T cells, NK cells) arise from hematopoietic stem cells (HSCs) in the bone marrow and mature in primary and secondary lymphoid organs.

Developmental Pathways

Cell TypeOriginPrimary Maturation SiteSecondary Maturation / Activation Sites
B cellsBone marrow (HSC → CLP → pro-B → pre-B → immature B)Bone marrow (central tolerance: receptor editing, deletion)Spleen (transitional → follicular/marginal zone), lymph nodes, MALT
T cellsBone marrow (HSC → CLP → thymic progenitors)Thymus (β-selection, positive/negative selection)Lymph nodes, spleen, mucosa (naïve → effector/memory upon antigen encounter)
NK cellsBone marrow (HSC → CLP → NK precursors)Bone marrow, lymph nodes, liver, thymus (partially)Circulation, spleen, liver, uterus (tissue-resident subsets)

Key Microenvironments

  • Bone marrow: CXCL12/CXCR4, SCF/c-Kit, IL-7, FLT3L maintain HSC niche and early lymphopoiesis.
  • Thymus: Cortical (cTEC) + medullary (mTEC) epithelial cells present self-peptides for selection; AIRE drives tissue-restricted antigen expression.
  • Secondary lymphoid organs: Follicular dendritic cells (B cell zones), fibroblastic reticular cells (T cell zones), chemokines (CXCL13, CCL19/21) organize architecture.

Clinical Relevance

  • Immunodeficiencies: SCID (block in development), DiGeorge (thymic aplasia), XLA (B cell block).
  • Malignancies: Leukemias/lymphomas reflect arrest at specific stages (e.g., pre-B ALL, T-ALL).
  • Therapeutics: CAR-T (autologous T cells engineered ex vivo), BTK inhibitors (B cell signaling), HSCT (replaces marrow niche).

Lymphopoiesis continues throughout life, though thymic output declines with age (involution), shifting T cell maintenance to peripheral proliferation.

Lymphoma - Related Articles